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Hepatitis C virus (HCV) can initiate infection by cell-free particle and cell-cell contact-dependent
transmission. In this study we use a novel infectious coculture system to examine these alternative modes
of infection. Cell-to-cell transmission is relatively resistant to anti-HCV glycoprotein monoclonal anti-
bodies and polyclonal immunoglobulin isolated from infected individuals, providing an effective strategy
for escaping host humoral immune responses. Chimeric viruses expressing the structural proteins rep-
resenting the seven major HCV genotypes demonstrate neutralizing antibody-resistant cell-to-cell trans-
mission. HCV entry is a multistep process involving numerous receptors. In this study we demonstrate
that, in contrast to earlier reports, CD81 and the tight-junction components claudin-1 and occludin are
all essential for both cell-free and cell-to-cell viral transmission. However, scavenger receptor BI (SR-BI)
has a more prominent role in cell-to-cell transmission of the virus, with SR-BI-specific antibodies and
small-molecule inhibitors showing preferential inhibition of this infection route. These observations
highlight the importance of targeting host cell receptors, in particular SR-BI, to control viral infection and
spread in the liver.
Hepatitis C virus (HCV) establishes chronic infection in 3%
of the world’s population, resulting in a progressive liver dis-
ease that is one of the leading indications for liver transplan-
tation. HCV has evolved several immune evasion strategies in
order to persist within the infected host (15, 20, 40), including
genetic escape from humoral immune responses (25, 46). How-
ever, functional constraints may restrict antigenic change in
some regions of the virally encoded E1E2 envelope glycopro-
teins, such as the CD81 receptor binding site (9, 11, 33). The
observation that glycoprotein-specific antibodies from chroni-
cally infected subjects neutralize the infectivity of laboratory
prototype HCV strains yet demonstrate a limited ability to
control HCV replication in vivo (40) suggest that additional
means of evading antibody responses may exist.
How virus particles disseminate within an immune-compe-
tent host has been a relatively neglected area of study; how-
ever, it is becoming increasingly clear that viruses employ mul-
tiple strategies to infect new target cells. Diffusion through the
pericellular environment or the vascular circulation introduces
a rate-limiting step in virus entry and exposes particles to the
humoral immune system. Consequently, a number of viruses
have evolved direct cell-to-cell modes of transmission that
maximize particle delivery, often in a neutralizing antibody
(nAb)-resistant manner (reviewed in reference 30).
We (44) and others (48) previously reported that HCV
strain JFH-1 could be transmitted via cell-free and cell-to-cell
routes in vitro. We extend these observations and show that
disruption of HCV particle assembly or physical separation of
target and producer cells ablates transmission, demonstrating
that intact virions are transferred via cell-cell contacts. HCV is
readily transmitted in the presence of patient-derived antibod-
ies that are able to neutralize cell-free virus infectivity. How-
ever, cell-to-cell transmission of HCV was sensitive to some
glycoprotein-specific monoclonal antibodies, notably those tar-
geting the first hypervariable region in E2 (HVR1). A diverse
panel of chimeric cell-cultured HCVs (HCVcc) representing
the seven major genotypes (12) infect via cell-to-cell contact,
demonstrating that this route of transmission is a universal
property of HCV.
HCV entry is a complex process that is dependent on host
cell molecules: scavenger receptor BI (SR-BI), tetraspanin
CD81, and the tight-junction proteins claudin-1 (CLDN1) and
occludin (5, 29, 43). Coexpression of human SR-BI, CD81,
claudin-1, and occludin renders nonliver cells permissive for
HCV entry, suggesting that these four proteins constitute the
minimal receptor requirement (34). We demonstrate that
CD81 and both tight-junction protein entry factors are re-
quired for cell-free and cell-to-cell transmission. However, an-
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tibodies and small-molecule entry inhibitors targeting SR-BI
(41) preferentially inhibit cell-to-cell transmission. Further-
more, increased SR-BI expression in the target cell augments
nAb-resistant infection, suggesting that SR-BI expression lev-
els limit cell-to-cell transmission. These findings shed new light
on the strategies employed by HCV to evade the humoral
immune response; they have major implications for the devel-
opment of targeted anti-glycoprotein immune therapies; and
they highlight the importance of targeting virus receptors, in
particular SR-BI, as a method to curtail HCV transmission and
immune evasion.
MATERIALS AND METHODS
Cell lines and antibodies. Huh-7.5 cells (C. Rice, Rockefeller University, New
York, NY) and Huh-7 Lunet cells (T. Pietschmann, Twincore, Hanover, Ger-
many [4]) were propagated in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% nonessential amino
acids. Huh-7.5 cells were transduced to overexpress SR-BI as previously de-
scribed (13). Rat anti-E2 monoclonal antibodies (MAbs) (9/27, 3/11, and 11/20)
and a control MAb (10/76b) were generated as previously described (16). IgG
was isolated from the serum samples of six chronically infected HCV patients by
use of protein G-conjugated Sepharose beads and was pooled (GE Healthcare,
United Kingdom). Anti-CD81 MAbs were generated by immunizing mice with
full-length purified CD81, and anti-SR-BI MAbs were a gift from Pfizer Ltd.
Anti-CLDN1 serum was raised by genetic immunization of Wistar rats using a
human CLDN1 cDNA expression vector, as previously described (22). Anti-
occludin was purchased from Invitrogen. Lentiviral short hairpin RNA (shRNA)
vectors (pLK01) specific for occludin were purchased from Open Biosystems
(Huntsville, AL).
Infectious coculture assay. Huh-7.5 cells were electroporated with in vitro-
transcribed full-length HCV RNA 72 h prior to their use in the assay (24, 47).
Unlabeled naïve target cells were seeded in a collagen-coated 12-well plate
(1.25 105 cells/well) and allowed to rest for 1 h at 37°C in the presence of either
control or neutralizing anti-glycoprotein specific antibodies. HCV-infected pro-
ducer cells were labeled with 5-chloromethylfluorescein diacetate (CMFDA)
(Invitrogen, CA) by incubating the cells at 37°C with 5 M CMFDA
(DMEM–3% FBS) for 30 min. Cells were washed and trypsinized. An equal
number of CMFDA-labeled producer cells were seeded into coculture with the
naïve target cells (total, 2.5  105 cells in 1 ml DMEM–3% FBS). “Indirect”
coculture assays were performed by seeding 2.5  105 cells in 6-well plates on
either side of a 0.1-m transwell insert (BD Falcon, CA). After 48 h, cocultured
cells were trypsinized, harvested, and fixed, and the culture medium was col-
lected to allow quantification of infectious cell-free virus. De novo transmission
events were determined by staining for HCV nonstructural protein NS5A and
were quantified by flow cytometry (see Fig. S1 in the supplemental material). To
investigate the role of receptors in HCV coculture transmission, receptor antag-
onists were added to cocultures alongside anti-glycoprotein nAbs. Inhibition by
each antagonist was calculated by comparison of transmission in treated and
control cells. For confocal imaging of viral transmission, the target and producer
cells were seeded onto collagen-coated 13-mm-diameter glass coverslips at a 1:20
ratio at 0.75 standard seeding density (1.75  105 cells/well).
Cell-free infectivity. To assess the infectivity of cell-free particles generated in
the coculture assay, the culture supernatant was titrated in a standard infectious
assay. Briefly, Huh-7.5 cells were seeded at 0.75 104/well of a 96-well plate and,
the following day, infected with a serially diluted sample. After 48 h, the cells
were stained for NS5A, foci were counted, and infectivity was expressed as the
number of focus-forming units (FFU) per milliliter.
Flow cytometry. For CD81 staining, 2 105 cells were incubated in phosphate-
buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.01%
sodium azide (PBA) for 20 min at 37°C. The CD81-specific MAb 2.s131 or an
irrelevant IgG control was incubated with cells in PBS for 30 min (2 g/ml) at
room temperature (RT), and unbound antibody was removed by washing. An
Alexa 488-conjugated anti-mouse secondary antibody (dilution, 1/1,000; Invitro-
gen, CA) was incubated for a further 30 min at RT, and the cells were washed
and fixed in 1% paraformaldehyde. To detect infection, cells were fixed with 1%
paraformaldehyde and permeabilized in a buffer containing PBS plus 1% BSA
and 0.5% saponin, and either an anti-NS5A 9E10 primary antibody (C. Rice,
Rockefeller University, New York, NY) or an irrelevant IgG control was added
for 30 min at RT. Unbound antibody was removed by washing, and the cells were
incubated for a further 30 min at RT with an Alexa Fluor RPE-conjugated
anti-mouse IgG2a isotype-specific secondary antibody (dilution, 1/1,000; Invitro-
gen, CA), followed by a buffer wash. Bound antibody was detected by flow
cytometry using a FACSCalibur instrument (BD Biosciences) and analyzed with
FlowJo software (TreeStar, Ashland, OR).
Laser scanning confocal microscopy. Control and shRNA-transduced Huh-7.5
cells were grown on glass coverslips and fixed with ice-cold methanol (occludin
and claudin-1) or 3% paraformaldehyde (CD81) 24 h postseeding. Primary
antibodies were applied for 1 h at room temperature. After two washes with PBS,
Alexa Fluor 488-conjugated anti-mouse, anti-rabbit, or anti-rat (Invitrogen, CA)
secondary antibody was applied for 1 h at room temperature. For imaging of
infectious coculture transmission, cells were fixed with ice-cold methanol and
stained for NS5A using 9E10 as the primary antibody and Alexa Fluor 594-
conjugated anti-mouse IgG2a as the secondary antibody. Cells were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen) for visualization
of nuclei and were mounted with ProLong Gold antifade reagent (Invitrogen).
Cells were viewed by laser scanning confocal microscopy on a Zeiss META head
confocal microscope with a 40 (coculture) or 60 (receptor expression) water
immersion objective.
RESULTS
HCV transmission in coculture is resistant to the neutral-
izing effects of anti-glycoprotein antibodies. We assessed the
sensitivity of HCV strain H77/JFH coculture transmission to a
panel of anti-E2 glycoprotein antibodies with diverse specific-
ities: rodent MAb 9/27 is specific for amino acids 396 to 407
within the first hypervariable region (HVR1); rodent MAbs
3/11 and 11/20 recognize linear epitopes comprising amino
acids 412 to 423 and 436 to 447, respectively, within the dis-
continuous CD81 binding site (16); and human MAbs CBH-
4G, HC-1, HC-11, and CBH-23 are specific for conformation-
dependent epitopes (19). In the majority of cases, cell-free
virus infectivity decreased with increasing nAb concentration;
95% of infectious cell-free particles were neutralized with
rodent MAbs and polyclonal HCV IgG (Fig. 1). In contrast,
the frequency of newly infected target cells was only modestly
reduced by the MAbs and polyclonal IgG. Although MAbs
9/27 and 11/20 exhibited the greatest activity against coculture
transmission, neither treatment was able to ablate transmission
at the maximum concentration tested, reaching 80 and
70% inhibition, respectively (Fig. 1). Similar results were
obtained with the human MAbs (see Fig. S2 in the supplemen-
tal material). These data demonstrate that HCV coculture
transmission is relatively resistant to a wide variety of glyco-
protein-specific antibodies, consistent with a role for direct
cell-to-cell transmission in nAb evasion and persistence in vivo.
nAb-resistant transmission requires cell contact and parti-
cle assembly. To examine the processes of transmission, we
used two methods to segregate target and producer cells within
the coculture (Fig. 2A). Assays were performed where the cell
seeding density was lowered to reduce the number of cell-cell
contacts. Alternatively, producer cells were grown on the lower
face of a transwell insert directly above the target cells to
prevent cell contact and to optimize the diffusion of cell-free
particles (Fig. 2A). In direct coculture, both cell-free and cell-
cell modes of transmission can occur; however, upon segrega-
tion of producer and target cells, HCV can be transmitted only
via the extracellular medium. In the standard assay, 40% of
target cells became infected, with an approximately equal ratio
of nAb-resistant and -sensitive routes of viral transmission
(Fig. 2A). However, nAb-resistant transmission was signifi-
cantly reduced at the lower seeding density and was abrogated
when the cells were separated by a transwell insert (Fig. 2A).
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These observations suggest that cell-free virus does not con-
tribute to nAb-resistant transmission, consistent with a direct
cell-to-cell mechanism of nAb evasion.
It is possible that HCV may evade anti-glycoprotein anti-
body responses via the direct transfer of RNA genomes be-
tween infected and naïve cells, thus negating the role of virions
in transmission. Indeed, the exosome secretion pathway rep-
resents an attractive target for localized spread of intracellular
pathogens (37). To test this model, we used a J6/JFH virus
encoding a deleted NS5A (domain III-del B) (42) that ex-
presses all of the viral proteins but lacks a critical phosphory-
lation event in NS5A required for particle assembly, providing
an ideal tool to investigate whether the nonencapsidated HCV
genome is capable of cell-to-cell spread. For the two genomic
constructs, the numbers of infected (NS5A) producer cells
were comparable [20.6% for J6/JFH and 24.6% for J6/JFH/
(del B)] (Fig. 2B). J6/JFH cocultures efficiently transmitted
infection to 21% of target cells after 48 h; however, no target
cells became infected when cocultured with J6/JFH/(del B)-
expressing cells, showing that nonencapsidated HCV genomes
are not transferred between cells (Fig. 2B). These observations
suggest that particle assembly is essential for HCV coculture
transmission.
nAb-resistant cell-to-cell transmission of diverse HCV ge-
notypes. We performed infectious coculture assays with a
panel of chimeric JFH viruses bearing the structural proteins
of genotype 1a to 7a viruses (12). The different viral strains
generated various levels of cell-free infectious virus (Fig. 3A)
that were generally predictive of transmission efficiency (Fig.
3C), in agreement with our earlier results demonstrating that
coculture transmission is dependent on infectious particles. To
neutralize cell-free particle infectivity, cross-reactive pooled
HCV patient IgG (300 g/ml) was added to the cocultures
(Fig. 3B). All of the viral strains demonstrated nAb-resistant
and -sensitive coculture transmission (Fig. 3C); however, dif-
ferences were noted in the relative mode of transmission be-
tween viral strains. These data suggest that nAb evasion by
direct cell-to-cell transfer of virions is a feature common to all
HCV genotypes.
nAb-resistant cell-to-cell transmission is CD81 dependent.
We have shown that cell-free virus infectivity is sensitive to the
neutralizing effect(s) of antibodies targeting the viral glycopro-
teins (Fig. 1); consequently, the addition of nAb to HCV co-
cultures enables us to monitor cell-to-cell transmission. We
employed an H77/JFH coculture assay in the presence or ab-
sence of neutralizing anti-E2 MAb 9/27 to assess the receptor
dependency of cell-to-cell transmission. We first examined
CD81 dependency using a panel of anti-receptor antibodies.
Prior to coculture, target cells were treated for 1 h either with
anti-CD81 MAbs specific for a range of conformation-depen-
dent epitopes or with a control antibody. All of the anti-CD81
MAbs inhibited nAb-sensitive and nAb-resistant transmission
by more than 90%, suggesting similar CD81 dependency for
the two routes of infection (Fig. 4A). Indeed, titration of anti-
CD81 MAb 2.s131 demonstrated comparable inhibition of
nAb-sensitive and nAb-resistant transmission (Fig. 4B). To
confirm that HCV coculture transmission is CD81 dependent,
we used a Huh-7-derived Lunet cell line that expresses low
levels of CD81 as measured by flow cytometry (Fig. 4E). Pa-
rental Lunet cells were resistant to HCV pseudoparticle and
cell-free HCVcc infection (data not shown), as previously re-
ported (21). H77/JFH- and SA13/JFH-infected producer cells
were cocultured with parental Huh-7 Lunet cells or those
transduced to express human CD81. Robust target cell infec-
tion was detected only in Huh-7 Lunet-CD81 cells, consistent
with CD81 being a critical HCV entry factor (Fig. 4C). How-
ever, a low number of SA13/JFH-infected Huh-7 Lunet cells
were detected, which may represent CD81-independent infec-
tion or could be attributed to the small number of Huh-7 Lunet
cells expressing low-level CD81 noted by flow cytometry (Fig.
FIG. 1. Effects of anti-glycoprotein antibodies on HCV H77/JFH
cell-free infectivity and coculture transmission. Anti-E2 MAbs 9/27,
3/11, and 11/20 (A) and pooled IgG isolated from 6 HCV-infected
individuals (B) were titrated in an HCV strain H77/JFH coculture
assay. Coculture transmission (open bars), expressed as the percentage
of target cells that were infected (left y axis), and the infectivity of
cell-free virus (filled bars), expressed as focus-forming units per milli-
liter (right y axis), were measured. All titrations were performed in
duplicate. Error bars indicate standard deviations. The data shown are
representative of 3 experiments.
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4E). Importantly, addition of anti-CD81 MAb 2.s131 ablated
SA13/JFH infection of Huh-7 Lunet cells, indicating that
CD81-independent infection did not occur. The ability to de-
tect SA13/JFH-infected Huh-7 Lunet cells may represent an
increased affinity of SA13 glycoproteins for CD81 or may sim-
ply reflect the higher infectivity of this chimeric virus (Fig. 3A).
We previously reported that HCV cell-to-cell transmission
could occur in the absence of CD81 (44); however, this is most
likely attributable to the previous experimental design. In our
earlier study, naïve target cells rather than producer cells were
CMFDA labeled; consequently, multicell aggregates of in-
fected producer and naïve target cells could be wrongly regis-
tered as positive transmission events (an example of this can be
found in Fig. S3 in the supplemental material). The current
experimental design eliminates these false-positive results. To
corroborate these findings, we imaged HCV-infected producer
cells cocultured with Huh-7 Lunet cells and found no evidence
for CD81-independent transmission (Fig. 4D).
nAb-resistant cell-to-cell transmission is dependent on
tight-junction proteins claudin-1 and occludin. The tight-junc-
tion proteins claudin-1 and occludin are thought to act during
the late stages of HCV entry, and there is limited evidence for
direct glycoprotein interaction(s) (10). We assessed the depen-
dency of HCV cell-to-cell transmission on claudin-1 by using a
using a recently reported rat polyclonal antiserum that can
inhibit cell-free virus infectivity (22). Target cells were treated
for 1 h with anti-claudin-1 or a control antiserum prior to
coculturing with Huh-7.5 cells infected by chimeric viruses
bearing the structural proteins of genotypes 1a, 1b, and 4a
(H77/JFH, J4/JFH, and ED43/JFH, respectively) (Fig. 5A).
Anti-claudin-1 inhibited nAb-sensitive and -resistant cell-to-
cell transmission of all three viruses, demonstrating a some-
what higher efficiency for nAb-sensitive transmission, suggest-
ing that both modes of transmission are claudin-1 dependent.
Due to the lack of antibodies targeting extracellular occludin
epitopes, we used shRNA to silence protein expression in
Huh-7.5 cells (Fig. 5B). Confocal imaging of transduced cells
showed a significant reduction in occludin expression, with no
observable effects on claudin-1, CD81, or SR-BI expression
levels (data not shown). Silencing of occludin in Huh-7.5 target
cells reduced both nAb-sensitive and nAb-resistant routes of
transmission (Fig. 5C). Thus, the two tight-junction proteins
have comparable roles in cell-free and cell-to-cell modes of
HCV transmission.
nAb-resistant cell-to-cell transmission is SR-BI dependent.
SR-BI is a receptor for high-density lipoprotein and is reported
to be involved in the early stages of HCV attachment and entry
(35, 39). We (14) and others (6, 49) have reported that anti-
SR-BI antibodies can inhibit cell-free HCV infectivity. To as-
sess the role of SR-BI in H77/JFH cell-free and cell-to-cell
transmission, we treated Huh-7.5 target cells with increasing
concentrations of an anti-SR-BI MAb. Interestingly, anti-
SR-BI demonstrated significantly greater inhibition of nAb-
resistant cell-to-cell transmission than of nAb-sensitive trans-
mission (Fig. 6A). To further understand the role of SR-BI in
cell-to-cell transmission, we employed a cell culture-adapted
JFH-1 mutant (the G451R mutant) that is relatively SR-BI
independent (14, 51). Coculture of JFH-1- and JFH-1 G451R-
infected producer and target cells confirmed the adapted phe-
notype of the G451R virus, with a greater capacity to transmit
than the parental virus (Fig. 6B). However, the G451R virus
demonstrated a significantly reduced nAb-resistant cell-to-cell
mode of transmission compared to wild-type JFH-1 (Fig. 6B).
Furthermore, anti-SR-BI significantly reduced JFH-1 cell-to-
cell transmission compared to nAb-sensitive cell-free infection
yet had minimal effect on JFH G451R transmission (Fig. 6C).
We previously reported that SR-BI overexpression increased
the susceptibility of Huh-7.5 cells to HCVcc infection (14); this
phenotype is accompanied by an increase in the size of JFH-
1-infected cell foci, indicative of enhanced cell-to-cell trans-
FIG. 2. nAb-resistant HCV transmission requires cell contact and infectious HCV particles. (A) The standard H77/JFH coculture assay was
modified either by performing the coculture at a low (0.25) seeding density or by seeding the target and producer cells on opposing faces of a
culture well and transwell insert. In both cases, a 1:1 target/producer ratio was maintained. The frequency of infected target cells in the absence
(nAb sensitive) or presence (nAb resistant) of MAb 9/27 at 4 g/ml is shown. The experiments were performed in duplicate, and error bars indicate
standard deviations. The data set is representative of 4 experiments. (B) J6/JFH and J6/JFH del B RNA were electroporated into Huh-7.5 cells.
After 72 h, the cells were labeled with CMFDA, and NS5A expression was measured either immediately (T  0 h) (left) or 48 h after coculture
with Huh-7.5 target cells (T  48 h) (right).
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mission, whereas JFH-1 G451R foci remained unaltered (Fig.
6D) (13). Given this observation, we employed these cells as
targets in an infectious coculture assay. HCV strains H77/JFH
and JFH-1 demonstrated a significant increase in nAb-resis-
tant cell-to-cell transmission in Huh-7 cells expressing 2-fold-
greater levels of SR-BI (Fig. 6E), suggesting that SR-BI levels
in Huh-7.5 hepatoma cells limit HCV cell-to-cell transmission.
To further investigate the role of SR-BI in HCV cell-to-cell
transmission, we studied the efficacies of two recently reported
entry inhibitors that bind SR-BI (41). Both compounds,
ITX5061 and ITX7650, significantly reduced H77/JFH nAb-
resistant cell-to-cell transmission and had a minimal effect on
nAb-sensitive cell-free transmission (Fig. 6F).
Receptor dependency of diverse HCV cell-to-cell transmis-
sion. We selected the chimeric JFH-1 viruses in which robust
(90%) cell-free neutralization was achieved (Fig. 4B) and
examined their sensitivities to receptor antagonists (Table 1).
Anti-CD81 MAb 2.s131 inhibited nAb-sensitive and -resistant
transmission of all HCV strains tested with comparable effi-
ciencies, with the exception of SA13/JFH. Targeting of SR-BI
by a receptor-specific antibody or ITX5061 displayed a broader
range of efficiencies, but with excellent agreement between the
two treatments. Notably, for all viruses, SR-BI antagonists
were more effective at reducing nAb-resistant cell-to-cell trans-
mission. In contrast, anti-CLDN1 demonstrated greater inhi-
bition of nAb-sensitive routes of viral transmission, with only a
minimal effect on either route of SA13/JFH or HK6a/JFH
transmission (Table 1). Although these findings suggest a spec-
trum of receptor dependencies among viral strains, SR-BI re-
mains an attractive therapeutic target, with ITX5061 displaying
cross-genotype inhibition of cell-to-cell transmission.
DISCUSSION
HCV persists in the face of a robust nAb response (40).
Indeed, the ability to evade the host immune responses is a
common feature of many viruses capable of establishing
chronic infection. In vitro model systems suggest that HCV is a
relatively sensitive target for antibody-mediated neutralization
(3, 24, 32, 50). We (44) and others (48) have reported efficient
HCV transmission in the presence of polyclonal patient IgG
and a limited number of anti-E2 MAbs, suggestive of direct
cell-to-cell transfer.
There are various mechanisms by which a virus particle may
be transmitted directly between cells. For instance, HIV and
herpes simplex virus (HSV) spread across specific cellular con-
tacts, and in the case of HIV, a virally induced structure
termed the virological synapse is formed (17). In contrast,
HSV exploits preexisting cellular contacts (45). Other viruses
remain tethered to the infected-cell surface, allowing directed
lateral movement to adjacent naïve target cells (8, 36, 38).
While these varied modes of cell-to-cell transmission are be-
lieved to provide an efficient alternative to cell-free infection,
they may also confer resistance to the humoral immune re-
sponse (27, 30).
The observation that HCV entry is dependent on two tight-
junction components (10, 34) offers the tantalizing possibility
that HCV may exploit such junctional contacts in transmission.
However, the Huh-7.5 cell line used in this study does not form
functional tight junctions (28), and further studies are required
to investigate the mechanism(s) of HCV transmission in po-
larized cell systems. Our observation that HCV E2 glycopro-
tein- and receptor-specific antibodies reduce cell-to-cell trans-
mission suggests that spread is not occurring across a sealed
cellular junction, which would exclude such antibodies (27).
HCV may exploit a contact structure similar to the virological
synapse of HIV (17), which has recently been shown to be
permeable to antibodies (27).
We find coculture transmission to be relatively insensitive to
neutralization by a panel of diverse anti-glycoprotein antibod-
FIG. 3. Diverse HCVcc transmission. Huh-7.5 cells were electro-
porated with a panel of chimeric JFH-1 HCV RNAs. At 72 h
postelectroporation, the cells were labeled with CMFDA and were
cocultured with Huh-7.5 target cells in the presence of control or
cross-reactive pooled patient HCV IgG at 300 g/ml for 48 h.
Extracellular medium was collected. (A) The levels of infectious
virus were quantified. (B) The percentage of neutralization by patient
HCV IgG was determined. (C) The stacked histograms display nAb-
resistant cell-to-cell transmission (open portions of bars) and nAb-
sensitive transmission (filled portions of bars) for each virus. The
infecting genotypes and strain designations are shown at the bottom.
All treatments were performed in duplicate, and error bars indicate
standard deviations. The data set is representative of 3 experiments.
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FIG. 4. HCV coculture transmission is CD81 dependent. (A) Anti-CD81 inhibition of H77/JFH coculture transmission. The stacked histogram
displays nAb-resistant cell-to-cell (open portion of bar) and nAb-sensitive (filled portion of bar) transmission in the presence of a control MAb
or one of five anti-CD81 MAbs (5 g/ml) specific for distinct epitopes. (B) Anti-CD81 MAb 2.s131 was titrated in a standard H77/JFH coculture
assay, and nAb-sensitive (f) and -resistant (‚) transmission is shown. All treatments were performed in duplicate, and error bars indicate standard
deviations. (C) H77/JFH- and SA13/JFH-infected producer cells were cocultured with Huh-7 Lunet cells or with cells transduced to express human
CD81 with or without anti-CD81 (10 g/ml MAb 2.s131). Representative flow cytometry plots are shown, and the percentages of target cells
infected are given in the upper left quadrants. (D) To corroborate the infectious coculture assay, cells were fixed, stained for NS5A, and imaged
by confocal microscopy. HCV-infected target cells (red), uninfected producer cells (green), and infected producer cells (orange) are clearly visible,
with cell nuclei shown in gray. White arrowheads indicate rare SA13/JFH-infected Lunet target cells. (E) Flow cytometric analysis of CD81
expression in parental Huh-7 Lunet cells and those transduced to express human CD81. Max, maximum.
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ies, whereas cell-free infectivity was readily eliminated (Fig. 1;
see also Fig. S1 in the supplemental material). nAb-resistant
transmission was prevented by separation of the target and
producer cells (Fig. 2A), providing compelling evidence that
this transmission occurs via direct cell-cell contacts. Cell-to-cell
transmission required particle assembly and did not occur via
the transfer of nonencapsidated HCV genomes (Fig. 2B). Fur-
thermore, we found that HCVcc chimeras representative of
seven genotypes were transmitted via cell-to-cell transmission
(Fig. 3), implying that this phenotype is common to all viral
strains.
We investigated the receptor dependency of HCV transmis-
sion and found that anti-CD81 MAbs inhibited both cell-free
and cell-to-cell infection, consistent with the idea that both
routes of transmission are CD81 dependent (Fig. 4). Huh-7
Lunet cells were resistant to infection both by H77/JFH and by
SA13/JFH. Furthermore, the low-level SA13/JFH infection of
Huh-7 Lunet cells was blocked by anti-CD81 MAb 2.s131,
suggesting that infection occurred in the minority of Huh-7
Lunet cells expressing low levels of CD81. This observation is
in contrast to our previous findings, and those of others, of
CD81-independent coculture transmission (18, 44, 48). Fur-
ther investigation into our observation that HCV could be
transmitted to CD81-negative HepG2 cells suggests that our
earlier finding was due to cell aggregates between labeled
target and producer cells yielding false-positive results, as
shown in Fig. S3 in the supplemental material.
The tight-junction components claudin-1 and occludin were
recently identified as entry factors for HCV (10, 34). Their
elevated expression at points of cellular contact make them
interesting candidates in directing cell-to-cell transmission. We
used an antiserum directed against the claudin-1 extracellular
domain, which disrupts the claudin-1/CD81 coreceptor associ-
ation(s) (22), to inhibit cell-free and cell-to-cell transmission
(Fig. 5). The antiserum exhibited moderate activity against
HCVcc chimeric viruses bearing the structural proteins of ge-
notypes 1a, 1b, and 4a and demonstrated greater efficacy
against nAb-sensitive viral transmission. shRNA silencing of
occludin expression in Huh-7.5 target cells reduced both nAb-
sensitive and nAb-resistant routes of HCV transmission (Fig.
5). Thus, both tight-junction proteins have a role in cell-to-cell
HCV transmission.
HCV particles are known to associate with host lipoproteins
(2, 7), and we previously reported that this association confers
nAb resistance (14). This may have implications for localized
spread by allowing HCV to remain associated with cells via
lipoprotein moieties (26). Interestingly, of all the anti-glyco-
protein MAbs tested, the anti-HVR1 MAb 9/27 demonstrated
TABLE 1. Sensitivities of chimeric JFH-1 viruses to receptor antagonists
Genotype JFHchimera
% Inhibition of virus transmission
Anti-CD81 Anti-CLDN1 Anti-SR-BI ITX5061
Sensitive Resistant Sensitive Resistant Sensitive Resistant Sensitive Resistant
1a H77 88 (1) 92 (2) 43 (1) 17 (3) 7 (6) 87 (1) 7 (12) 81 (1)
1b J4 82 (1) 88 (1) 55 (5) 32 (1) 7 (14) 79 (1) 8 (2) 73 (1)
4a ED43 97 (1) 94 (2) 54 (5) 36 (4) 7 (2) 75 (2) 4 (5) 69 (1)
5a SA13 46 (4) 92 (1) 8 (5) 22 (2) 0 (4) 44 (2) 0 (0) 41 (2)
6a HK6a 94 (1) 93 (1) 10 (1) 1 (1) 10 (2) 34 (7) 15 (1) 40 (3)
FIG. 5. Role for claudin-1 and occludin in HCV coculture transmission. Infectious coculture assays were performed with chimeric
HCV-infected producer cells bearing the structural proteins of genotypes 1a (H77), 1b (J4), and 4a (ED43). (A) Target cells were incubated
with polyclonal rat anti-claudin-1 serum (dilution, 1/100) prior to coculture. Inhibition of nAb-sensitive (filled bars) and nAb-resistant (open
bars) transmission is shown. (B) Huh-7.5 cells were transduced with irrelevant lentiviruses or lentiviruses expressing occludin shRNA (sh
occludin). One hundred twenty hours later, the cells were fixed, permeabilized, and stained for occludin expression. (C) Huh-7.5 target cells
either transduced with irrelevant control shRNA or silenced with occludin shRNA were cocultured with H77/JFH-infected producer cells,
and the frequency of nAb-sensitive (filled portions of bars) and nAb-resistant (open portions of bars) transmission was quantified by flow
cytometry. All treatments were performed in duplicate; error bars indicate standard deviations; and the data set is representative of two
experiments.
602 BRIMACOMBE ET AL. J. VIROL.
the greatest potential for reducing cell-to-cell transmission,
suggesting that antibodies targeting HVR1 may limit cell-cell
transfer of infection. However, in vivo, HCV can escape anti-
HVR1 responses by conventional genetic escape (25, 46).
SR-BI is thought to play an important role in HCV attach-
ment and entry via its interaction with the E2 glycoprotein
(35). SR-BI antagonists display preferential inhibition of cell-
to-cell transmission of HCV (Fig. 6 and Table 1). A mutant
JFH-1 G451R virus with limited SR-BI dependence (14) dem-
onstrated minimal cell-to-cell transmission (Fig. 6B). Further-
more, overexpression of SR-BI in Huh-7.5 cells promoted cell-
to-cell transmission (Fig. 6D and E). Taken together, these
data demonstrate that SR-BI plays an essential role in cell-to-
cell transmission, and targeting of this receptor may limit nAb-
FIG. 6. HCV coculture transmission is SR-BI dependent. (A) An anti-SR-BI MAb was titrated in a standard H77/JFH coculture assay.
Inhibition of nAb-sensitive (f) and nAb-resistant (‚) infection is shown. (B) JFH-1- and JFH-1 G451R-infected producer cells were
cocultured with Huh-7.5 target cells in the presence or absence of neutralizing patient IgG (300 g/ml). The stacked histogram displays
nAb-resistant cell-to-cell transmission (open portions of bars) and nAb-sensitive transmission (filled portions of bars) for each virus.
(C) Effect of an anti-SR-BI MAb (1 g/ml) on JFH-1 and JFH-1 G451 nAb-resistant (open bars) and -sensitive (filled bars) transmission.
(D) Parental Huh-7.5 cells (open bars) or Huh-7.5 cells overexpressing SR-BI (filled bars) were infected with JFH-1 or JFH-1 G451R for
72 h in a standard cell-free infectious assay. HCV-positive cells were enumerated by immunofluorescent microscopy, allowing quantification
of infected-cell focus size. The histograms display the percentages of total infection residing in small (1 to 2 cells), medium (3 to 10 cells),
large (11 to 30 cells), or very large (31 to 100 cells) infected-cell foci. (E) H77/JFH- and JFH-1-infected producer cells were cocultured with
parental Huh-7.5 cells or with Huh-7.5 cells transduced to overexpress SR-BI (), in the presence or absence of neutralizing patient IgG
(300 g/ml), and infected target cells were quantified. H77/JFH and JFH-1 nAb-resistant infection of cells overexpressing SR-BI was
significantly increased (P, 0.0096 and 0.0037, respectively). (F) Effects of the SR-BI-specific small molecules ITX5061 and ITX7650 (1 M)
on H77/JFH nAb-sensitive (filled bars) and -resistant (open bars) transmission. Treatments were performed in duplicate, and error bars
indicate standard deviations.
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resistant modes of HCV transmission. SR-BI-specific com-
pounds have been developed to treat atherosclerosis (1, 31),
and SR-BI, unlike the other HCV receptors, is predominantly
expressed in the liver (39), reducing the possibility for off-
target effects.
It is clear that cell-to-cell transmission of pathogens facili-
tates immune evasion and persistence. The localized spread of
HCV may be an adaptation to exploit the compact and highly
ordered environment of the liver. This conclusion is supported
by the recent observation of HCV-infected foci in liver biopsy
samples from HCV-infected patients (23). It is important to
remember that extracellular forms of HCV are most likely
responsible for spread between hosts and for liver allograft
reinfection following transplantation. However, cell-to-cell
transmission may represent the dominant route of virus dis-
semination within chronically infected individuals. Our find-
ings raise a number of issues that will require further consid-
eration for the design and preclinical evaluation of HCV
glycoprotein-specific antibody and therapeutic B-cell vaccines,
since it appears that HCV has evolved methods to evade such
immune surveillance. In contrast, targeting of the viral recep-
tors or entry factors, in particular SR-BI, may provide a means
of augmenting the host immune response by inhibiting cell-to-
cell transmission.
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